out of DVR with 7.8% in new one at 6.89

still in PACB as had higher entry in DVR at 1.64

talk about being screwed on a market order of 100 shares

taking a flyer on some sept $65 MNST (Monster Beverage)calls at .93

with the indices pushing up into resistance I am hesistant to keep something too long

I'm out of KTOS at 5.30 6% less my $15 round trip

in KTOS 1000 @ 5

out of EPAX with 8% gain plus one quarterly dividend

WHo do you use for A/H trading. I keep missing these huge runs as I resist paying way up on the open

osg rockets out of the gate leaving me behind

out of RT with 4.75% gain

missed my sell limit on RT by .08....trying to get my 8%

out of ATAX with a 13% gain plus one quarterly dividend

in at 6.34 for 1000 shares

will be time to start buying mndo again just before the run up to the annual dividend in early 2013. If you don't mind dead money for a few months this is usually a good trade imo.

I am still waiting for the pullback that didnt happen :)

on a plane when RSH was released missed that. Out of emms with 14% plus gains

I liked this part:
Jim Hoyes, the President of EMD Serono (the biopharmaceutical division of Merck KGaA, the German chemical and pharmaceutical company) summed it up during his speech at BIO, commenting, “Part of that is recognizing what we aren’t as good at.” The large cap life science companies are getting anxious, and regenerative medicine is poised to address the growing pipeline issue.

At our annual shareholders meeting, we told you that it was not likely a matter of whether we will partner one or more of our programs (such as the RPE program), but rather, when. We need to move further into our trials to really capitalize on the intrinsic value of our RPE cell therapy, but it is evident from the general tenor at BIO and our individual conversations that we are on the right track. We will continue to keep these lines of communication open – updating potential partners on our progress, and using those meetings to learn more about the issues that would be important to any diligence around a deal – and taking that input and using it to fine tune our regulatory and intellectual property strategies.

entered fold at 6.20

looks like good support down around 6.18

anyone looking to play fold now that it is under 6.25

just sold DAKT with 11% gain

got some emms at 1.93 and waiting on the other with a limit order...looks like it might come down to greet me

getting back in today

agreed....the look back at these prices down the road and hopefully we will all be kicking ourselves we did not buy more

watching for a short aqueeze run on MNKD to collect on that trade.

bought some .8102s...replaced the .93s I sold a few weeks ago

need a little volume and lets get INO back into the 50s

mnkd needs to break through 2.78...multiple tries but no luck so far

out of SNTA with 9.5% gainer....in MNKD

got some SNTA at 5.85, still in VICL and HEK and back to B/E on both

out of hero and xco both for 11% gainers

ACT Announces Second Patient with Stargardt’s Disease Treated in EU Clinical Trial
Second Patient of First Cohort Treated with RPE Cells Derived from Human Embryonic Stem Cells at Moorfields Eye Hospital in London

Press Release: Advanced Cell Technology, Inc. – 1 hour 4 minutes agoShare0EmailPrintCompanies:Advanced Cell Technology Inc.RELATED QUOTESSymbol Price Change
ACTC 0.062 0.00


MARLBOROUGH, Mass.--(BUSINESS WIRE)--

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment of the second patient in its Phase 1/2 clinical trial for Stargardt’s macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The surgery was performed on Friday, June 29 at Moorfields Eye Hospital in London, the same site as the first patient treatment in January, by a team of surgeons led by Professor James Bainbridge, consultant surgeon at Moorfields and Chair of Retinal Studies at University College London. The procedure was successfully performed without any complications. ACT and Moorfields Eye Hospital recently received clearance from the Data and Safety Monitoring Board (DSMB) to treat the final two patients in the first cohort of this clinical trial.

“We are very pleased to continue our forward momentum with both our U.S. trials and our European trial,” commented Gary Rabin, chairman and CEO. “It was less than a month ago that we received DSMB approval to treat the second and third patients in our E.U. trial, and it is very gratifying to have already completed dosing of the second. It is a pleasure to be working with Professor Bainbridge and the rest of his team at Moorfields Eye Hospital, and we continue to be encouraged by the steady progress of the trial thus far.”

The Phase 1/2 trial is designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation in patients with SMD at 12 months, the study’s primary endpoint. It will involve a total of 12 patients, with cohorts of three patients each in an ascending dosage format. It is similar in design to the U.S. trial for SMD that was initiated in July 2011.

The European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has officially designated ACT's human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells as an orphan medicinal product for the treatment of Stargardt's Macular Dystrophy (SMD).

More information on the status of the company’s clinical trials will be posted today on Mr. Rabin’s Chairman’s blog.

About Stargardt’s Disease
Stargardt’s disease or Stargardt’s Macular Dystrophy is a genetic disease that causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium, which is the site of damage that the company believes the hESC-derived RPE may be able to target for repair after administration.

About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2011. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.

out of CRY with a small gain of 1%

missed FES by a penny

xco up in pre-market

I still hold vicl....almost back to b/e. also in opk and keep thining about bailing with a small loss put Frost keeps buying

still in xco and in hero

sold that to soon and I was happy with the 10+ gain I had.

still holding it.... With Nat gas up today this could be a nice gain